8-K: Avinger Reports Q2 2024 Results, Implements Cost Reductions and Advances Coronary Device Development

Avinger announced its second quarter 2024 financial results, highlighted by a revenue of $1.8 million, a 20% gross margin, and progress in its coronary product line development.

Summary

• Avinger reported a revenue of $1.8 million for the second quarter of 2024, slightly down from $1.9 million in the previous quarter and $2.0 million in the same quarter of 2023.
• The company's gross margin increased to 20% in Q2 2024, up from 18% in Q1 2024 but down from 30% in Q2 2023.
• Operating expenses were reduced to $4.5 million in Q2 2024, compared to $5.4 million in Q1 2024 and $4.3 million in Q2 2023.
• Avinger implemented a cost reduction program in June 2024, which included a 24% reduction in headcount.
• The company's net loss for the quarter was $4.4 million, an improvement from $5.5 million in the previous quarter but worse than the $4.2 million loss in the same quarter of 2023.
• Adjusted EBITDA loss was $3.8 million for the quarter, compared to a loss of $3.9 million in the previous quarter and $3.4 million in the same quarter of 2023.
• Avinger completed the conversion of $11 million of debt into shares of convertible preferred stock, reducing the outstanding principal amount of debt to $2.6 million.
• The company secured up to $24 million in additional growth financing, with $6 million funded in June 2024 and up to an additional $18 million available based on the exercise of coronary clinical milestone-linked warrants.
• Avinger is progressing with Phase III verification and validation studies for its coronary CTO-crossing system, with an IDE submission anticipated in the third quarter of 2024.
• The company is also building product inventory for the full commercial launch of the new Pantheris LV device.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments such as cost reductions, debt conversion, and progress in product development, the financial results show a decrease in revenue and a net loss. The sentiment is neutral to slightly negative.

Positives

• Gross margin improved sequentially to 20% in the second quarter of 2024.
• Operating expenses decreased to $4.5 million in the second quarter of 2024.
• The company successfully reduced its debt by converting $11 million into preferred stock.
• Avinger secured up to $24 million in additional growth financing.
• The company is on track to submit an IDE application for its coronary CTO-crossing system by the end of the third quarter of 2024.
• Avinger is preparing to launch the new Pantheris LV device.
• The appointment of Dr. Thomas Davis as Chief Medical Officer is a positive step for the company's clinical strategy.

Negatives

• Revenue decreased slightly to $1.8 million in the second quarter of 2024 compared to the previous quarter and the same quarter of 2023.
• Gross margin of 20% in Q2 2024 is lower than the 30% reported in Q2 2023.
• The company reported a net loss of $4.4 million for the second quarter of 2024.
• Adjusted EBITDA loss was $3.8 million for the quarter.

Risks

• The company is dependent on a limited number of products.
• There are resource requirements related to Pantheris, Tigereye, and the Lightbox imaging console.
• The outcome of clinical trial results could impact the company.
• The adoption of Avinger's products by physicians is crucial for success.
• The company's ability to obtain regulatory approvals for its products is a risk.
• The company's ability to access established reimbursement codes for both coronary CTO-crossing and OCT-diagnostic imaging is a risk.

Future Outlook

Avinger expects improved gross margin and reduced operating costs in the second half of 2024. The company anticipates submitting an IDE application for its coronary CTO-crossing system by the end of the third quarter of 2024 and plans to launch the new Pantheris LV device.

Management Comments

• Jeff Soinski, Avinger's President and CEO, stated that the Phase III verification and validation studies for the coronary CTO solution remain on track for filing an IDE application by the end of the third quarter.
• Jeff Soinski also mentioned that the company intends to offer superior, simplified, and more predictable clinical outcomes by applying new iterations of their clinically proven proprietary image-guided technologies.
• Management believes that their OCT-image-guided PAD solutions continue to offer the most reliable outcomes in the category.

Industry Context

Avinger is operating in the competitive medical device industry, specifically in the vascular disease treatment market. The company's focus on image-guided, catheter-based systems for both peripheral and coronary artery disease positions it to compete with other companies offering similar technologies. The development of a coronary CTO-crossing system addresses a significant unmet need in the market.

Comparison to Industry Standards

• Avinger's revenue of $1.8 million is relatively low compared to larger medical device companies like Medtronic or Boston Scientific, which report billions in quarterly revenue.
• The 20% gross margin is lower than the industry average for medical device companies, which often exceeds 50%. Companies like Intuitive Surgical and Stryker typically have higher gross margins.
• Avinger's focus on image-guided technology is similar to companies like Philips and Abbott, which also offer advanced imaging solutions for vascular procedures.
• The development of a coronary CTO-crossing system puts Avinger in competition with companies like Boston Scientific and Abbott, which also have products in the interventional cardiology space.
• The $24 million in growth financing is a significant amount for a company of Avinger's size, but it is still small compared to the capital raises of larger medical device companies.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the financial results and the potential for future growth.
• Employees were impacted by the 24% reduction in headcount.
• Customers will benefit from the new Pantheris LV device and the coronary CTO-crossing system.
• Creditors will be impacted by the debt conversion and the new financing.

Next Steps

• Avinger will continue Phase III verification and validation studies for its coronary CTO-crossing system.
• The company plans to submit an IDE application for the coronary CTO-crossing system by the end of the third quarter of 2024.
• Avinger will build product inventory for the full commercial launch of the new Pantheris LV device.
• The company will focus on supporting its existing peripheral device users.
• Avinger will continue to streamline its operating cost profile.

Key Dates

Keywords

Avinger, Vascular Disease, Medical Device, Coronary Artery Disease, Peripheral Artery Disease, CTO, Atherectomy, IDE Submission, Gross Margin, Operating Expenses, Debt Conversion, Growth Financing, Pantheris LV, OCT Imaging